- Clinical Trials
- April 2025
- 100 Pages
Global
From €1790EUR$2,000USD£1,530GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2237EUR$2,500USD£1,913GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
India
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
North America
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Germany
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Italy
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Oman
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
France
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
United States
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Spain
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Iran
From €4250EUR$4,750USD£3,635GBP

Exenatide is a drug used to treat endocrine and metabolic disorders. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to regulate glucose levels in the body. Exenatide is used to treat type 2 diabetes, and is administered as a subcutaneous injection. It works by stimulating the release of insulin from the pancreas, and by slowing the rate of glucose absorption from the gastrointestinal tract.
Exenatide is available in two forms: a long-acting version (Bydureon) and a short-acting version (Byetta). Both versions are used to improve glycemic control in adults with type 2 diabetes, and can be used in combination with other diabetes medications. Exenatide has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes.
Exenatide is marketed by several companies, including AstraZeneca, Eli Lilly, and Novo Nordisk. It is also available as a generic drug in some countries. Show Less Read more